Mode
Text Size
Log in / Sign up
Phase 4 N=210 Randomized Triple-blind Treatment

Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit

Post-operative Craniotomy Patients · Carotid Endarterectomy and Carotid Artery Stenosis Patients · Post-op Spine Patients Admitted to the NCCU · Endovascular Patients Undergoing Intracranial Intervention · Traumatic Brain Injuries NPO for at Least 12 Hours

Enrolled (actual)
210
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcome: Primary: Narcotic Requirement After Surgery — 123.5; 134.2 Morphine Equivalents

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Intravenous acetaminophen (Drug); Placebo for IV acetaminophen (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Utah
Primary completion
Nov 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Narcotic Requirement After Surgery
123.5; 134.2

Summary

To assess the efficacy of an intravenous nonnarcotic pain medication on controlling patient pain. To assess the effect of an intravenous nonnarcotic pain medication on patient sedation levels in neurocritically ill patients. To assess the effect of an intravenous nonnarcotic pain medication on common side effects seen in patients taking other intravenous narcotic pain medication in the neurocritical care unit.

Eligibility Criteria

Inclusion Criteria

  • > 45 kg (amenable to adult dosing)
  • all traumatic brain injuries NPO for at least 12 hours
  • all post-operative craniotomy patients
  • all non-operative subarachnoid hemorrhage, intraparenchymal hemorrhage, and stroke patients
  • all carotid endarterectomy and carotid artery stenosis patients
  • all endovascular patients undergoing intracranial intervention
  • all post-op spine patients admitted to the NCCU

Exclusion Criteria

  • documented allergy to acetaminophen
  • documented severe hepatic impairment (Child-Pugh score > 6) or severe hepatic disease (hepatitis)
  • documented severe renal impairment (CrCl < 30 ml/min) Blood tests will be performed prior to study procedures that will ensure patients do not have renal impairment.
  • patients who are pregnant or breast feeding
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01948505). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search